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Abstract: One of the most common viral infections in humans is caused by herpes simplex 
virus (HSV). It can easily be treated with nucleoside analogues (e.g., acyclovir), but 
resistant strains are on the rise. Naturally occurring antimicrobial peptides have been 
demonstrated to possess antiviral activity against HSV. New evidence has also indicated 
that these host defence peptides are able to selectively stimulate the innate immune system 
to fight of infections. This review will focus on the anti-HSV activity of such peptides 
(both natural and synthetic), describe their mode of action and their clinical potential. 
Keywords: cationic host defence peptides; antiviral therapy; herpes; antimicrobial 
peptides; innate defense regulators; immune stimulation 
 
1. Introduction 
Introduction of the therapeutic use of penicillin during World War II followed by the discovery and 
development of other antibiotics targeting bacterial, and later also viral and fungal pathogens, have had 
a tremendous impact on human life expectancy. However, infectious diseases remain the main cause of 
morbidity and mortality accounting for nearly one-third of the global deaths annually  [1]. In addition 
to this, there have been reports of alarming increases in the prevalence of drug-resistant clinical viral 
strains, especially in cases related to HIV, highlighting the urgent need for new antiviral intervention 
strategies. Despite these facts, there has been a decline in the number of new drugs that has been 
introduced to the market, and the pharmaceutical industry has largely withdrawn from the field of  
anti-infective discovery and development. In parallel, the academic interest in the field has bloomed, 
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leading to new drug strategies for microbial intervention, e.g., antibodies and small molecule agonists 
and antagonists, and the success of these ventures has been reviewed elsewhere  [2-7]. Another very 
promising strategy is tailored around the so-called host defence peptides (HDPs; also called cationic 
antimicrobial peptides), and this is currently being pursued by several small and mid-sized 
biotechnology companies. In large, this review will discuss HDPs and their inhibitory activity against 
herpes simplex virus (HSV), in addition to some promising peptides in clinical trials, supporting the 
idea that derivatives of HDPs may one day serve as a valid choice for HSV intervention.  
2. Tailoring antiviral peptide drugs 
Numerous strategies can be envisioned for the design of peptide drugs that are able to inhibit herpes 
simplex virus infection. For example, one can create peptides that directly target the virus particle  
(i.e., viral envelope or glycoproteins), or one can design antiviral peptides that target the host cell  
(i.e., blocking viral attachment and/or more specific entry receptors) through peptide-protein 
interaction. A third strategy would be to create peptides that could stimulate the host innate immune 
system to oppose and control the viral infection.  
Human herpes simplex virus comes in two flavors, type 1 or type 2 (HSV-1 and HSV-2), and they 
are the primary agents of recurrent facial and genital herpetic lesions, respectively  [8,9]. They are also 
the two most widely studied human herpes viruses, leaving a very detailed picture of how these viruses 
infect and replicate in the host cells. In brief, initiation of HSV infection involves attachment of viral 
glycoprotein C (gC) and/or glycoprotein B (gB) to heparan sulfate on the host cell surface 
(Figure 1)  [10,11]. Although interaction with heparan sulfate can be viewed as somewhat unspecific, 
it is well recognized that heparan sulfate functions as an attachment receptor for both HSV-1 and 
HSV-2  [12], explaining the low HSV infectivity of cells deficient in heparan sulfate 
expression  [10,13,14]. However, viral attachment to heparan sulfate does not automatically enable 
viral entry. The entry process requires viral glycoprotein D (gD) interaction with one or several  
co-receptor molecules on the host cell surface  [15], i.e., (1) HveA/HVEM (herpes virus entry 
mediator)  [16,17], (2) nectin-2/HveB/PRR2/, nectin-1/HveC/PRR1 (poliovirus receptor related 
immunoglobulin)  [17,18] and nectin-1/HIgR (herpes immunoglobulin-like receptor)  [19] and (3)  
3-O-sulfated heparan sulfate (3-O-HS)  [20,21] (Figure 1). The viral envelope then fuses with the host 
cell membrane with the help of viral gB, gD, and a heterodimer of gH and gL, resulting in release of 
the viral tegument proteins and the viral capsid into the cytosol. After the initial infection and a 
successful replication cycle, the viral progeny can be released either through host cell lysis, exocytosis 
or it can be transferred across cell junctions to the neighboring cell (cell-to-cell spread). The latter 
process is not fully understood, though it is clear that by performing cell-to-cell spread, the virus 
avoids neutralizing antibodies and other elements of the hosts’ immune system  [22]. Despite the 
limited knowledge currently available about this process, viral mutants deficient in expressing gE or 
gI, are also significantly suppressed in their ability to produce plaques  [22,23], supporting the 
hypothesis that gE and gI mediate HSV transfer across cell junction by interactions with cell junction 
components  [24].  
Besides targeting the viral particle or the viral attachment and entry mechanism, another valid but 
ambitious strategy would be to target the host innate immune system for preventing and curing an 
Viruses 2009, 1                            
 
 
941
infection. This strategy has been made possible through the discovery of specific pathogen recognition 
receptor families such as the Toll-like receptors, peptidoglycan recognition proteins and intracellular 
sensors of microbial components, e.g., the Nod-like receptors and the retinoic acid-inducible  
gene-I-like receptors  [25,26]. The innate immune system has evolved through evolution and is 
intrinsically conserved and highly efficient, considering the relative infrequency in which infectious 
diseases occur, thus rendering it a very suitable target for the development of novel antiviral drugs.  
An excellent example of an approved immunemodulator for treatment of viral infections are the 
cytokine-based recombinant and modified forms of interferon-α (e.g., pegylated IFN-α), currently 
primarily being used for chronic hepatitis infections, but also being administered in severe cases of 
herpes-associated diseases in immunosuppressed patients. Another immune stimulant, Isoprinosine, 
enhances T cell proliferation and activity, and is also approved for treatment of HSV, though it is 
significantly less active than other more traditional herpes drugs  [27]. Despite this increased 
understanding of the antiviral immune mechanisms and the success of pegylated IFN-α and 
Isoprinosine, a very limited number of drugs have been approved for medical use against HSV in the 
last few decades. Hence, the current trends for HSV treatment is still mainly targeting the viral 
replication process with Acyclovir  [28] or synthetic analogues thereof  [29].  
3. Host defence peptides 
Evolution has resulted in a finely tuned defence system relying on the interplay between the 
germline-encoded innate immunity and antigen-specific adaptive immunity mechanisms, a process 
which is known to involving a specter of different cytokines. Recently it has been recognized that 
many host defence peptides are able to modulate these cytokine levels, reinforcing their role as 
regulators of innate immune and inflammatory responses of mammals, amphibians and insects  
 [30-32]. Being such fundamental signature molecules of host defence explains why virtually all 
species of life produces host defence peptides in moderate to high concentrations. More than 1000 
naturally occurring host defence peptides have been described to date, and the majority of these are 
covered in databases for eukaryotic host defence peptides, e.g., the site at the University of Trieste 
(http://www.bbcm.units.it/~tossi/pag1.htm) and the AMPer site (http://cnbi2.ca/cgi-bin/amp.pl)  [33]. 
Despite their widespread distribution, these peptides are typically short (12 to 50 amino acids), 
carrying a net positive charge (+ 2 to + 9) due to excess basic arginine and/or lysine residues, and 
contain up to 50% hydrophobic amino acids. They are generally divided into four structural categories 
(i.e., -sheets, -helices, loop- and extended-structures) (Figure 2), creating amphiphilic 
conformations upon interactions with lipid membranes, enabling membrane damage and/or 
penetration. 
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Figure 1. Known properties of antiviral/immunomodulatory host defense peptides. The figure illustrates possible targets in a single cell (A) and at the systemic level (B). 
HDPs may contribute their antiviral activity through interference with viral attachment and entry (1). The viral envelope contains more than a dozen viral glycoproteins and 
five of them (gB, gC, gD, gH and gL) have been shown to participate in viral entry. Binding of virus to the cell is mediated by the binding of gB and/or gC to heparan sulfate 
chains on the cell surface proteoglycans. This facilitates the binding of gD to one of its cell surface receptors: HVEM, nectin-1, nectin-2, or specific sites on heparan sulfate 
generated by 3-O-sulfotransferases. Binding of gD to any one of these receptors triggers fusion of the viral envelope with the cell membrane. This membrane fusion requires 
the action of gB and a gH-gL heterodimer as well as gD and the gD receptor. Transport of HSV though the cytoplasm to the nucleus may also be targeted (2). The HSV 
capsid buds through the inner nuclear membrane forming an enveloped virion particle. Egress of virions from host cell may occur by either of the two general pathways; 
either budding through the outer nuclear membrane and vesicular transport through the Golgi apparatus to the exterior of the cell (3) or de-enveloping of the capsid through 
the nuclear membrane and capsid budding into the Golgi apparatus, forming an enveloped virion, which is transported to the surface by vesicular movement (4). The virus 
may also be targeted indirectly through HDP stimulation or suppression of cellular signaling cascades (5), interference with gene transcription (6) or alteration of different 
effector molecules produced by the cells and/or degranulation (7). Antiviral responses to HDP treatment may also have systemic effects, as it is well established that high 
concentrations of HDPs are released from activated neutrophil secretory vesicles (8). HDPs like LL-37 can also alter TLR-induced responses reducing pro-inflammatory 
mediators (9) and inhibit apoptosis of neutrophils (10). HDP may also trigger differentiation of dendritic cells (11) and monocytes to macrophages (12, 13). HDP-activated 
macrophages are also known to release several chemokines (14) promoting recruitment of leukocytes into the afflicted area (15). HDPs like LL-37 also promote expression 
of co-stimulatory molecules on dendritic cells leading to expression of Th1 cytokine IL-12 (16). 
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Initially cationic host defence peptides were investigated due to their direct ability to kill multidrug-
resistant bacteria through extremely rapid mechanisms engaging and inhibiting multiple targets  [34]. 
It was quickly realized that these peptides also carried a lytic ability, perforating bacterial membranes 
through “aggregate”  [35], “toroidal pore”  [36], “barrel-stave”  [37], or “carpet”  [38] mechanistic 
models (Figure 3). This naturally fuelled research investigating the peptides potential to lyse viral 
envelopes, as well. Later studies have also demonstrated the ability of many peptides (e.g., PR39,  
LL-37, LfcinB) to translocate across the cytoplasmic membrane of human cells while others are 
constitutively produced and stored as precursors inside host cell vacuoles  [39-41]. Cellular uptake of 
these HDPs can result in gene/protein stimulation influencing host cell antiviral mechanisms  [42], or 
might block viral gene/protein expression  [43].  
Figure 2. Structural classes of antimicrobial peptides; (A) mixed structure of Plectasin, a 
defensin-like molecule (PDB code 1ZFU)  [44], (B) β-looped lactoferricin (PDB code 
1LFC)  [45], (C) -helical human cathelicidin LL-37 (PDB code 2K6O)  [46], (D) 
extended indolicidin (PDB code 1G89)  [47]. The figures have been prepared with use of 
the graphic program MolMol 2K.1  [48]. 
 
 
4. Antiviral activity of HDPs 
Shortly after the discovery of the antibacterial potential of HDPs, it was confirmed that members 
from all four structural classes of HDPs also demonstrated the ability to inhibit viral infection, 
primarily affecting enveloped RNA and DNA viruses. Later it has been confirmed that viral infection 
with non-enveloped viruses, like adenovirus, feline calicivirus and echovirus 6 also can be 
inhibited  [49-52]. Specifically for HSV, it was demonstrated that some -helical peptides,  
i.e., cecropins, clavanins, and the human cathelicidin LL-37, caused minimal or no viral inactivation   
A B
C D
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[53-55], while other -helical peptides like magainins, dermaseptin and melittin, demonstrated quite 
potent anti-HSV activity (Table 1)  [55-58]. Conversely, -sheet peptides like defensins, tachyplesin, 
protegrins and the -turn peptide lactoferricin, have all shown high activity towards HSV 
(Table 1)  [55,59-64]. Consequently, it appears impossible to predict peptide antiviral activity based on 
the primary or secondary structure of the peptides. However, the antiviral mechanism appears to be 
related to the viral adsorption and entry process  [58], or to a direct effect on the viral 
envelope  [56,65] indicating that the peptides ability to form stable amphiphilic conformation plays a 
crucial role for their antiviral activity.  
Figure 3. Mechanism of action of antimicrobial peptides targeting bacterial lipid 
membranes. The bacterial membrane is represented by the orange lipid bilayer with 
peptides illustrated as dual colored cylinders, with a hydrophilic region (red) and a 
hydrophobic region (blue). The arrangement of peptides on the surface of the lipid layer is 
hypothesized to drive four different membrane permeabilization mechanisms: the 
“aggregate” model (1), the “torodal pore” model (2), the “barrel-stave” model (3) and the 
“carpet” model (4).  
 
 
5. Structural requirements for HDP antiviral activity 
Several groups have made synthetic analogues of several naturally occurring HDPs to generate a 
firmer understanding of the structural requirements for peptide antiviral activity by changing chemical 
parameters such as charge and aromatic amino acids, as peptide antiviral activity often is correlated 
with both high cationic- and amphiphilic potential  [55,60,66,67]. Other characteristics such as 
hydrophobicity, have been investigated in a hybrid peptide of cecropin A and magainin-2  [68], while 
D- or L-amino acids substitutions have been studied on a set of -defensins  [64].  
Substitution analysis studies have been reported for several different peptide classes, i.e., the  
-looped lactoferricin, an artificial -helical peptide and the rigid cyclic -defensin. In the lactoferricin 
study, the relationship between HSV activity and peptide net charge and aromatic amino acids were 
investigated. The authors concluded that the spatial positioning of the charged residues were crucial 
for a potent peptide antiviral activity  [61] while the aromatic residues were of less importance for anti-
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HSV activity  [69]. The importance of a specific spatial presentation of the charged residues were 
reinforced by results from the substitution analysis study on the synthetic -helical peptides  [66,69]. 
These findings were also in accordance with results from Giansanti et al.  [70] and Yasin et al.  [64], 
which in separate studies on lactoferrin/transferrin derived peptides and -defensin analogues, 
respectively, concluded that the spatial conformation and presentation of positively charged residues 
were critical, but not sufficient for antiviral activity  [64,70]. There are also results indicating that the 
rigidity of the peptides may contribute to the antiviral activity. Both lactoferricin and polyphemusin 
consist of -structures stabilized by one and two internal disulfide bridges, respectively, and results 
have demonstrated that these stabilizing disulfide bridges are crucial for the peptides antiviral 
activity  [61,67,82] (Figure 2, Table 1). However, a comparative study of peptides which clearly adopt 
different secondary structures have demonstrated that many of these peptides possess analogous 
antiviral modes of action, indicating that interaction with their target are independent of their 
structure  [61,66]. The most likely explanation is that these HDPs are prone to adopt amphipathic 
conformations, which we have proposed are intrinsic to their antiviral activity.  
6. Mode of action – blocking of viral entry by heparan sulfate interaction  
Glycosaminoglycans are negatively charged molecules found in all tissue types: in intracellular 
granules, extracellular matrix, and on the cell surface  [86-88]. As a result of their chemical 
composition, these molecules facilitate an interaction with almost anything carrying a slight cationic 
charge including small cations, proteins and peptides  [89-95]. Heparan sulfate is the most important 
glycosaminoglycan and it has been demonstrated to serve as an important attachment receptor for 
several viruses including HSV  [96,97]. Thus, it has been hypothesized that  blocking of heparan 
sulfate can reduce viral attachment and consequently decrease the severity of the infection  [10,11]. 
This has later been confirmed by using recombinant cells deficient in heparan sulfate expression, 
where it was demonstrated that the susceptibility to HSV infection was knocked down by 80%  [12]. 
Similarly, by enzymatic removal of cellular glycosaminoglycans, it has also been demonstrated that 
HSV cell-to-cell spread, a viral mechanism used by HSV to evade the hosts’ immune regime, could be 
decreased  [98], thus increasing the value of a potential drug targeting glycosaminoglycans. Inhibition 
of heparan sulfate biosynthesis (e.g., heparin, heparinase I and sodium chlorate) has also demonstrated 
the ability to inhibit human Cytomegalovirus infection in a dose-dependent manner  [99]. Additionally, 
glycosaminoglycans have also been shown to be of major importance for HIV entry and 
replication  [100], although they seem to be less important for HIV attachment to the host cell. Several 
HDPs, like human -defensin, LL-37, magainin, bovine and human lactoferricin, have all been shown 
to interact with different glycosaminoglycans  [101-105]. The sequence and structural diversity in 
these peptides suggest that the critical factor driving the interaction with glycosaminoglycan is the 
position of charged residues in the secondary structure. This is in accordance with the structural 
peptide studies correlating peptide affinity for heparan sulfate and anti-HSV activity, demonstrating 
that the affinity for heparan sulfate is only partly correlated with the peptides’ net charge  [61,66]. In 
addition, it has been demonstrated that peptide analogues with arginine residues had a significantly 
higher affinity for glycosaminoglycan than comparable peptide analogues substituted with 
lysine  [66,106-108]. 
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Table 1. Selected examples of antiviral peptides. 
Peptide Structure Source Virus Primary amino acid sequence Proposed antiviral mechanism References 
Magainin -helix Frog HSV GIGKFLHSAKKFGKAFVGEIMNS Cellular target  [56,57,71] 
Cecropin A1 -helix Insect HSV GWLKKIGKKIERVGQHTRDATIQGLGVAQ
QAANVAATAR 
Cellular target  [57,72] 
Melittin -helix Bee HSV GIGAVLKVLTTGLPALISWIKRKRQQ Cellular target  [55,57,73] 
LL-37 -helix Human HSV LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNL
VPRTES 
Weak viral inactivation  [55,74] 
Brevinin-1 -helix Frog HSV FLPVLAGIAAKVVPALFC1KITKKC1 Viral inactivation  [55,75] 
 defensin Cyclic -sheet Primate / human HSV G1FC2RC3LC4RRGVC4RC3IC2TR1 Binds gB and blocks viral attachment  [64,76] 
Defensin -sheet Human / rabbit HSV 
HCMV
MPC1SC2KKYC3DPWEVIDGSC2GLFNSKYIC3
C1REK 
Interacts with HSV membrane/ glycoprotein and 
cellular target but not heparan sulfate 
Inactivates viral particle 
 [60,63,64,77,78] 
Dermaseptin -sheet Frog HSV ALWKTMLKKLGTMALHAGKAALGAAADT
ISQGTQ 
Activity at virus-cell interface  [58,79] 
Tachyplesin -sheet Horse shoe crab HSV KWC1FRVC2YRGIC2YRRC1R Viral inactivation  [55,80] 
Protegrin -sheet Human / 
porcine 
HSV RGGRLC1YC2RRRFC2VC1VGR Viral inactivation  [55,81] 
Lactoferricin -turn Human / bovine 
 
HSV 
HCMV
FKC1RRWQWRMKKLGAPSITC1VRRAFA Blocks heparan sulfate, but a secondary effect  
has also been indicated. 
Activity at virus-cell interface 
 [59,61,82-85] 
Indolicidin Extended Bovine HSV ILPWKWPWWPWRR Targets viral membrane / glycoprotein  [47,57] 
Note: The designation HSV indicates either type 1 or 2 (HSV-1 or HSV-2), or both types; human cytomegalovirus (HCMV) is another member of the human herpes virus 
family. The primary amino acid compositions of these peptides are given in one letter code. Cysteines forming disulfide bonds (or N-terminal to C-terminal linking) are 
numbered with subscript numbers to indicate their pairing. Boldface indicates cationic (blue) and anionic (red) amino acid residues. 
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HDP targeting of heparan sulfate is further supported by results from studies where peptide and 
virus were pre-incubated prior to infection. These studies demonstrate no increase in the peptide 
antiviral activity, confirming that cellular heparan sulfate was the primary target for these HDPs and 
not the viral interaction partner (i.e., gC and/or gB)  [39]. It should also be mentioned that HDPs 
exhibit different protective effects against HSV-1 and HSV-2, probably attributable to the combined 
effects of the peptides’ primary and secondary structures  [59,61,66,109], something that has also been 
reported for other polycationic and even for polyanionic compounds  [110,111]. Naturally, these 
differences may also reflect on the viral specificity of particular receptor molecules, and the 
differential ability of the peptides to interact with the different viral receptors.  
7. Blocking of viral entry and cell-to-cell spread 
Direct interaction between the HDPs and the glycoproteins in the viral envelope has been proposed 
to influence the viral attachment and entry. However, not many of the traditional peptides have been 
confirmed to actually possess this ability, though it has been proposed that dermaseptin can 
demonstrate anti-HSV activity through blocking of the attachment/adsorption/fusion phase of the HSV 
infection  [58]. It has also been demonstrated that human neutrophil peptide (HNP)-1 (an -defensin) 
neutralizes HSV-1 in a time-, temperature- and pH- dependent manner, in a process which is also 
antagonized by serum  [60]. By pre-incubation of HNP-1 and HSV-2 prior to infection, it has been 
demonstrated that the infection can be reduced by >98%, while pre-treatment of the host cells with 
HNP-1 had no obvious effect on the anti-HSV activity. As the peptide still prevented viral entry, 
though not through competition for cellular heparan sulfate interaction, it is indicated that viral 
glycoproteins involved in membrane fusion may be the target  [63]. Similarly, it has been 
demonstrated that -defensin (retrocyclin 2) directly binds HSV-2 glycoprotein B with high affinity, 
thus protecting the cells from HSV-2 infection  [64]. Another possible interaction between the HDPs 
and the viral particle is through a peptide-lipid interaction, as HDPs are known for their ability to 
interact with lipid membranes, causing conformational changes leading to destabilization of the 
bacterial membrane, translocation of HDP, pore formation or lysis  [112,113]. Indolicidin and 
dermaseptin is known to directly inactivate HIV-1 through membrane/envelope disruption  [65,114]. 
Similar membrane disruption has been observed on vesicular stomatitis virus (VSV) after exposure to 
tachyplesin-1. This viral destruction is concentration-, time- and temperature- dependent, and electron 
micrographs of the tachyplesin-1 treated VSV particles showed naked and damaged virions, 
confirming the direct effect of the peptide on the viral envelope. Interestingly, treatment of HSV-1 and 
HSV-2 with tachyplesin-1 demonstrated no such effect on the viral envelope  [115], indicating that the 
herpes envelope is relatively resistant to peptide damage. Experiments with cecropin, magainin, and 
lactoferricin are supporting this by demonstrating no direct peptide damage on the HSV 
envelope  [57]. Electron micrographs of bovine lactoferricin exposed HSV also demonstrate a lack of 
direct interactions between the peptide and the viral particle (Jenssen, H; Unpublished results). 
Cell-to-cell spread of HSV is one of the important mechanisms utilized by this virus to reduce 
cellular damage, consequently avoiding the initiation of a massive inflammatory response and silently 
escaping the immune system. It is well documented that several HDPs can reduce the cell-to-cell 
spread of HSV. For example, studies with rabbit -defensin NP-1 and bovine lactoferricin, have 
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demonstrated that these peptides inhibit both primary entry and cell-to-cell spread of HSV  [39,63,66]. 
However, HDPs acting as inhibitors that only reduce part of the viral entry or spread will probably 
have limited success from a clinical point of view.  
Continued discovery of new HSV entry receptors as reported by Perez et al. (i.e., human B5 
protein) will complicate the design of novel anti-HSV drugs  [116]. Though this new receptor can be 
blocked by binding of an -helical peptide in a coiled-coil formation  [117] and probably also by other  
-helical cationic peptides  [66] effectively, there is hardly a valid alternative for completely blocking 
HSV entry unless a cocktail approach targeting all the attachment and entry receptors is adopted for 
drug design.  
8. Intracellular targets and host cell stimulation 
It is widely acknowledged that direct antimicrobial activities of HDPs are strongly antagonized by 
physiological salt concentrations, i.e., 100mM monovalent- and 2mM divalent cations (as well as 
polyanions like glycosaminoglycans)  [118]. Salts may also influence the peptide structure and 
consequently their association with anionic cell molecules, thus affecting their activity  [119]. In 
addition to this, it has been demonstrated that the antiviral mode of action of -defensin is serum 
dependent  [120]. Together, this argues for the hypothesis that the systemic effects found with many 
HDPs are primarily a result of their immunomodulatory properties and to a lesser extent the peptides 
direct antimicrobial activity.  
Rapid intracellular localization of the HDPs may support this hypothesis, and transmission electron 
microscopy studies have confirmed intracellular translocation of lactoferricin  [39,98]. Bovine 
lactoferricin was also able to enter glycosaminoglycan-deficient cells in an energy-independent 
manner  [39]. Similar experiments by Futaki et al. indicate that this mechanism is dependent on 
arginine content, a known feature of nuclear localization signals  [121-123]. Human lactoferricin has 
multiple arginine residues  [124] which probably contributes to the shuttling of this peptide into the 
nucleus where it can bind DNA. Due to many peptides’ abilities to interact with DNA, one might 
speculate that this directly influences viral nucleic acid synthesis, as has been shown for polyphemusin 
T22 and lactoferrin  [125-128]. Consistent with this, the antiviral peptides LL-37 and indolicidin can 
both act as nuclear localization signals to translocate anti-sense nucleic acids  [129].  
Conversely, it is also known that HDPs have immunomodulatory activities which include the  
up-regulation of interferons and chemokines  [118,120,130,131]. Thus many antiviral peptides might 
exert their activities in part by stimulating the antiviral immune system of the host cell. In addition to 
stimulating host cell responses, HDPs may also interfere with viral-triggered processes in the target 
cell. For example, it has been demonstrated that transport of HSV-2 tegument protein VP16 to the cell 
nucleus and consequent expression of ICP4 effectively are blocked in the presence of rabbit  
-defensin (NP-1)  [63]. Taken together, this prompted us to hypothesize that the most promising 
mechanism of HDPs in antiviral therapy is probably through stimulation of the host immune system as 
a mode of promoting pathogen clearance rather than direct blocking of viral attachment, entry and/or 
spread (Figure 1).  
However, targeting the host immune system as a strategy for microbial intervention is not solely a 
strategically ingenious idea; it may also have a very devastating outcome, due to the extremely delicate 
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balance between pro- and anti- inflammatory reactions. Thus, any type of immunotherapy should be 
initiated with extreme caution. It is also well documented that immune-suppressive chemicals and 
irradiation treatment will leave the patients vulnerable to new infections  [132]. Additionally, there are 
also potential side effects with immune modulating drugs, like an inappropriate dysregulation of the 
immune system causing either sepsis or a cytokine storm  [133]. In addition, HDPs like human  
β-defensin-2 and LL-37 can both induce histamine release  [134] and many HDP derived peptides 
have demonstrated the ability to trigger apoptosis, or programmed cell death. It has also been 
suggested that over-expression of certain HDPs, like LL-37 in the skin will lead to an uncontrolled 
interferon response that will initiate the autoimmune skin inflammation in psoriasis patients  [135]. 
While in patients suffering from a chronic inflammation of the intestine (Crohn’s disease)  [136], it has 
been demonstrated that the epithelial cells lining the intestine are deficient in secreting β-defensins-2 
and -3  [137,138] and LL-37  [139], resulting in an elevated level of luminal bacteria, thus allowing the 
natural microbial flora to trigger inflammation  [140]. 
Despite these challenges, there are also several advantages in targeting the host innate immune 
system with HDP derivatives. The host immune mechanism is very general with broad spectrum 
activity. Thus, by optimizing a drug for immune modulation, it is likely that the drug will have a 
similar broad spectrum potential. As the pathogen itself is not targeted, there is very little chance of 
resistance development. HDP derivatives are generally well tolerated due to their chemical nature, 
though questions have been raised regarding the peptides’ poor pharmacokinetics profile. However 
strategies like N-methylation and pegylation have demonstrated the potential of significantly 
improving the oral bioavailability, metabolic stability and intestinal permeability of peptide 
drugs  [141-143].  
9. Adjuvant potential of HDP derived peptides 
Vaccination dates back more than two hundred years to when Edward Jenner successfully vaccinated 
his patients against smallpox virus through exposure to cowpox virus, and the technique has since proven 
extremely effective as a public health initiative, reducing the devastating magnitude of several infectious 
diseases. However, there are only efficient vaccines against a handful of the human infectious diseases. In 
light of the immune stimulating role of natural HDPs and the ability of human cathelicidin (LL-37) to 
modulate dendritic cell differentiation and induced polarization, it has been proposed that HDPs may 
serve as novel adjuvants  [144] in the production of more effective vaccines. 
Traditional adjuvants have the tendency to cause undesirable injection site reactions as it is believed 
that it is necessary to retain the antigen at the site of injection as a depot to achieve an enhanced 
immune reaction  [145]. As an example, vaccine development against respiratory syncytial virus 
(RSV) has been a struggle as the traditional adjuvants also have had a tendency to cause a Th2 biased 
immune response  [146,147]. However, by reformulating the recombinant RSV fusion protein (DeltaF) 
with CpG oligodeozynucleotides, polyphosphazene and a HDP (indolicidin), it has been demonstrated 
that immunized mice developed a significantly higher level of RSV neutralizing antibodies compared 
to mice immunized with recombinant DeltaF alone  [148]. Physical characterization of these vaccines 
has also indicated that the formulated vaccine demonstrated increased immunogenicity due to complex 
formation between the antigen and the adjuvant  [149]. The adjuvant-antigen complex formation was 
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rapid and appears to be less dependent on the peptide sequence, indicating that this process is 
relatively nonspecific. However, by testing several synthetic HDP derived peptides, it has been 
demonstrated that the increased immune response of these adjuvant complexes are peptide sequence 
specific  [150,151]. Similar complex formation has also been alluded to in two separate vaccine 
formulation studies using artificial cationic peptides. In these studies, it was suggested that the 
peptides formed a transient depot at the site of injection, enhancing the association of antigen with 
antigen presenting cells  [152,153]. However, it should be mentioned that one of these peptides, KLK-
L5-KLK, also has been demonstrated to cause membrane rearrangement  [154], facilitating uptake of 
oligonucleotides into the cellular compartments  [155]. Thus, it is fair to conclude that HDPs as a 
vaccine adjuvant carries a very interesting potential, though the current understanding of the 
mechanism behind this adjuvant activity is somewhat limited.  
10. Clinical potential of HDPs as antiviral therapeutics  
Host defence peptides are an interesting class of agents with under-explored potential as antiviral 
therapeutics. Pioneer work exploring antiviral properties of naturally occurring HDPs reported 
interesting and promising results for several classes of peptides against numerous subfamilies of both 
naked and enveloped viruses. Despite the possibility of success from this work minor advancement has 
occurred beyond funneling these compounds into pre-clinical development. A handful of biotech 
companies, e.g., Magainin Pharmaceuticals (now Genaera; http://www.genaera.com/), Micrologix 
(now Migenix; http://www.migenix.com/) and IntraBiotics Pharmaceuticals 
(http://www.intrabiotics.com/) attempted to drive HDPs through clinical trial testing, but the majority 
of these pioneer projects were terminated after decades of struggle.  
Peptides are traditionally viewed as very costly to manufacture, which has probably limited their 
potential for clinical exploration and use. However, a convergent strategy of synthesizing peptides 
through selection and assembly of peptide segments has proven to be useful in reducing cost and 
enabling large scale production for the commercial market. The best example of this is Roche 
(http://www.roche.com/index.htm) and Trimeris’ (http://www.trimeris.com/) joint success in large 
scale production of the HIV fusion inhibitor, T-20 (Efuvirtide, Fuzeon), by solid- and solution-phase 
hybrid synthesis  [156,157]. T-20 is a 36 amino acid peptide that binds to a region of the HIV envelope 
glycoprotein gp41, thus, it is capable of blocking viral entry into CD4+ T-cells. The drug is currently 
only licensed for use in patients for whom other HIV medications are losing effectiveness, due in part 
to the limited annual production capacity (3.7 metric tons in 2005 providing treatment for ~47,000 
patients). Still, a more viable business strategy is probably the biotechnological approaches taken by 
Novozymes (Bagsvœrd, Denmark, http://www.novozymes.com/en), using a recombinant fungal 
expression platform for large scale production of plectasin with therapeutic purity in compliance with 
good manufacturing practices  [44]. Plectasin is a 40 amino acid defensin-like peptide (Table 2) and a 
derivative of this (NZ2114) is currently being launched into pre-clinical development in collaboration 
between Novozymes and Sanofi-Aventis (Bridgewater, NJ, USA). Though NZ2114 is being 
investigated for its potential as a direct Gram-positive antimicrobial  [158], this study may also 
encourage introduction of other defensin-like peptides into the clinic.  
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Table 2. Selected examples of immunomodulatory and antimicrobial peptides in clinical trials or developmental stages. 
Drug Sequence Description/Status/Results Company & reference 
Plectasin 
NZ2114 
GFGC1NGPWDEDDMQC2HN
HC3KSIKGYKGGYC1AKGGF
VC2KC3Y-COOH        (Plectasin)
Preclinical: A variant of plectasin which has demonstrated potent Gram-positive effect 
in systemic pneumococcal and streptococcal infections. 
Novozymes AS / Sanofi-Aventis 
(Bagsvœrd, Denmark), 
www.novozymes.com 
Zadaxin / 
Thymosin 1 / 
thymalfasin 
AC-SDAAVDTSSEITTKDLK
EKKEVVEEAEN-COOH 
Phase III / approved: A 28-mer bovine HDP intended for directed therapy targeting 
chronic hepatitis B and C viruses. It promotes MHC class I expression, 
interleukin-2 and interferon- secretion, proliferation and activation of CD4 Th1, 
CD8, and NK cells. It also decreases Th2 cytokines (e.g., interleukin-4 and 
interleukin-10) that are counter productive to viral infections. 
SciClone / Sigma-Tau (Foster 
City, CA, USA), 
www.hcvadvocate.org, 
www.scicloneinternational.com 
Oglufanide 
disodium / 
IM862 
EW-COOH Phase II: A di-peptide for direct targeting chronic hepatitis C virus. Administration of 
an intranasal synthetic formulation of IM862 has demonstrated to reverses the 
suppression of the immune system. 
Implicit Bioscience (Toowong, 
QLD, Australia), 
www.hcvadvocate.org 
SCV-07 γ-D-glutamyl-L-tryptophan Phase IIa: SCV-07 has demonstrated promising results as a mono-therapy in patients 
with chronic hepatitis C virus infection. 
SciClone 
www.scicloneinternational.com 
Note: Amino acid sequences are given in one-letter code. Cysteines forming disulfide bonds are numbered with subscripts to indicate their pairings. N- and 
C-terminal modifications are indicated before the hyphen in the front or after the hyphen at the end of the sequence. 
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Despite the limited clinical success of the cationic peptide drugs pioneering this field, several new 
ventures have subsequently been launched, with a strong involvement from academic labs worldwide. 
Consequently, though there are no current peptide drugs targeting herpes infections, there are several 
examples of viral diseases being treated with peptide drugs, illustrating the potential of driving these 
types of drugs into the clinic. For example, hepatitis B and C viruses are targeted with Thymosin 1 
(ZADAXIN, Thymalfasin), a 28 amino acid peptide originally isolated from calf thymus  [159] 
(Figure 4, Table 2). It is currently being synthezised on solid phase by SciClone Pharmaceuticals 
International Ltd. (Causeway Bay, Hong Kong, China, http://www.scicloneinternational.com/) and 
approved for clinical use in more than 30 countries. Thymosin 1 enhances Th1 cytokine production 
along with T cell differentiation and maturation, augmenting the involvement of a specific T helper 
cell response in antiviral defence  [160]. Another peptide being developed for hepatitis C virus 
treatment is the di-peptide (L-Glu-L-Trp, IM862) isolated from the calf thymic peptide complex 
Thymalin  [161] (Figure 4, Table 2). Implicit Biosciences (Brisbane, QLD, Australia) is currently 
pursuing a sodium carboxylated salt of this peptide (Oglufanide disodium) in Phase IIa clinical trials. 
IM862 is known to have immunomodulatory properties  [162] and it has also recently been 
demonstrated that lipidation of IM862 will increase the bioavailability of the drug  [163]. Similarly, a 
synthetic analogue of IM862 named SCV-07 (gamma-D-glutamyl-L-tryptophan) (Figure 4, Table 2) 
has also been proven to have immune stimulating properties on Th1 cells, which are essential for 
clearance of viral infections. Recently, SciClone Pharmaceuticals International Ltd. reported positive 
results from Phase IIa clinical studies using SCV-07 as a monotherapy in patients with chronic 
hepatitis C infection. It has also been demonstrated recently that SCV-07 can significantly reduce 
recurrent herpetic lesions when administered orally but not subcutaneously in a guinea pig model of 
recurrent genital herpes simplex virus 2  [164].  
This clearly indicates the potential for broad spectrum activity of such immune modulatory peptide 
drugs. Increasing knowledge and a broader understanding of the underlying mechanisms in the 
immune system together with technological advancements will probably advance the development of 
novel HDPs as alternative anti-infective drugs and one day also enable use of peptide-derived drugs in 
the treatment of HSV related infections.  
11. Conclusion 
We are rapidly approaching a crossroad where previously successful drug regimes are starting to 
fail and drug-resistant herpes strains are appearing. Thus, it is time to pursue alternative approaches 
and HDP-derived peptides may be a golden alternative. Many would argue that peptides acting as 
entry blockers of HSV for treatment are facing critical disadvantages as the virus easily adapts and is 
able to infect its host cells using several different receptors.  
A more promising strategy would probably be to tailor peptide drugs promoting host cell immune 
responses. As HSV infections, in most cases, are self-resolving, innate defence regulators are prone to 
accelerate this process, reducing the infection period, thus having a tremendous positive impact on the 
patient for a reduced chance of resistance development. However, the concept of using HDP-derived 
drugs for antiviral treatment is still in its infancy and will require continued research and 
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implementation of new technology platforms, i.e., bioinformatics, to identify targets and generate a 
better understanding of the intrinsically complex immune response cascades.  
Figure 4. Antiviral peptides in clinical trials. (A) Zadaxin, (B) IM862 and (C) SCV-07 
are all compounds which have demonstrated promising results as immune modulators for 
treatment of patients with chronic hepatitis C virus infections. 
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